TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: daytime ABP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: night-time ABP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PF1+2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: average %V̇O2 peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average %HRmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat and CHO utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anastomotic leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: effects on general functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: effect on amphetamine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of FDT-VFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Odds ratio for glaucoma in heavy computer users with refractive errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk for development of CNV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Drusen reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful radial artery cannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to successful cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical mucus quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve 50% recovery of digital skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve 70% recovery of digital skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: fatigue increase
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: blood lactate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood glucose increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NDI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SF-36-BP
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SF-36-PCS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall peak power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall mean power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeated sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pericardial fat volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of oral-loaded divalproex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of oral-loaded divalproex
Endpoint domain: Adverse events/effects
Primary endpoint: low density lipoprotein (LDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ox‐LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sICAM‐1 levels after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sVCAM‐1 levels after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: newborn's birth size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reflex response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: elastic path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on simple interrupted suturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Performance on running suture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NASA workload scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Development delay (DD)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: rate of spontaneous delivery before 34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Employment status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Days of drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concern about drug use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 6-month neurologic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in LDLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: LDLP/HDLP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Median time to PCP transition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of ECU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death and major disability (modified Rankin Scale score≥3)
Endpoint domain: Mortality/survival
Primary endpoint: Health-related quality of life (HQoL) as measured by KCCQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of cardiovascular death or hospital admission for HF
Endpoint domain: Mortality/survival
Primary endpoint: Return to sports
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in mania symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transfer reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean methaemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Musculoskeletal comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Injury rates
Endpoint domain: Adverse events/effects
Primary endpoint: Workers' compensation costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fractional Flow Reserve (FFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Instantaneous Wave-Free Ratio (iFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting Pd/Pa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal voluntary isometric force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: plasma alanine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: resting pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual acuity testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-stimulus rebound of the approximately 20 Hz beta rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude increase of the pre-central N(30) SEP component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Strength increase of the 30 ms SEF cortical source
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sick leave days reported
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Awareness of alcohol policies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of smokers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per month of adequate symptom control
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acute rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Graft losses
Endpoint domain: Adverse events/effects
Primary endpoint: perceived risk of cervical cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BCR-free probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Metastasis
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: pain release
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Loss of muscle mass (arm muscle circumference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cardiovascular mortality (CVM)
Endpoint domain: Mortality/survival
Primary endpoint: neuropathy symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neuropathy impairment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sural sensory nerve amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decreased fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: changes in microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: changes in FENa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: changes in free water clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cost saving per intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Antibiotic prescribing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global illness severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: English vocabulary learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FF levels of HIF1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean duration of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mature oocytes retrieved in selected follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Arithmetic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maze performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total prostate volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition zone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition zone index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse or recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Moderate or severe adverse side effect
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in CMTNS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deoxysphinganine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumonia TESAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Pneumonia TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative urethral stricture rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absolute AIx reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete suppression of delayed emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection from nausea in the delayed phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events of mild intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Bone-specific alkaline phosphatase (BSAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of reported health symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative VTE rate
Endpoint domain: Mortality/survival
Primary endpoint: Improvements in child behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in caregiver antisocial and aggressive behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of chromium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentrations of cobalt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of HLA DR(+) CD8(+) T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incident ischemic stroke or TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: illness perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stent failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to stent failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early stent failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in smooth muscle actin stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Anginal class improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of MACE
Endpoint domain: Adverse events/effects
Primary endpoint: Serum albumin concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of sepsis or bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Reversal of type 1 HRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of neuromuscular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Train-of-four ratio (T4/T1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Carrier rate of Gm (23+) allotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Over-representation of Gm (23-) allotype in CP patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of R131 allele of FcgammaR IIa polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-HBs concentrations >/=10 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: geometric mean anti-HBs concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recall of drug benefits and risks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: eating disorder psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: pathogen eradication rate for MRSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anterior tibalis muscle latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean back pain scores at 30 min after injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in pain scores after 30 min according to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal satisfaction from the analgesic effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: median percentage reduction in lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: median absolute reduction in lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: T-cell responses by ELISpot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pathologic complete response (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year Freedom From Treatment Failure (FFTF) rate
Endpoint domain: Mortality/survival
Primary endpoint: gain in tibial trabecular bone content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cortical bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: No episode of acute rejection or graft loss
Endpoint domain: Mortality/survival
Primary endpoint: accuracy of assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation preferences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intensive care unit admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Preference for life-prolonging chemotherapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight loss of 5% of total body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intestinal absorption of energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: intestinal absorption of carbohydrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: intestinal absorption of fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Understanding of the concept of brain death
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: median time of stent patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' survival
Endpoint domain: Mortality/survival
Primary endpoint: average tumor size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality-Adjusted Life-Years (QALYs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SIGH-SAD sums
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body sway during gait or running
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year overall survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Oswestry Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma IGF‐I concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GH responses to sumatriptan, sodium valproate and L‐Dopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GH‐RH‐induced GH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total 25-OHD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavioral intentions regarding alcohol and cigarette use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time weaned off vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time on mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of distant metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean adaptive dimension of the ASR scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of GIM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of biopsies required per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: KTA-M scores after cooking lessons
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete response (no nausea and vomiting)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes